Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples